Table 2.
Characteristics of studies and therapy
| Study | Number of centers (country) | Enrolment; years | Prospective design | Autologous HSCT following HDCT |
||
|---|---|---|---|---|---|---|
| Drugs | Consolidation vs salvage vs NR; N | PBSCT vs BMT vs NR; N | ||||
| Aggregate comparative data | ||||||
| Bui-Nguyen et al21 | 16 (France) | 2000–2008 | Yes | Ca-Et-If | 38 vs 0 vs 0 | 38 vs 0 vs 0 |
| Aggregate case series data | ||||||
| Bertuzzi et al22 | 1 (Italy) | 1997–2002 | Yes | Me-Mi-Th | 10 vs 0 vs 0 | 10 vs 0 vs 0 |
| Bisogno et al23 | >1 (Italy) | 1999–2008 | Yes | Cy-Me-Th | 14 vs 0 vs 0 | 14 vs 0 vs 0 |
| Blay et al24 | 1 (France) | 1988–1994 | Yes | Ci-Et-If | 0 vs 0 vs 24 | 0 vs 0 vs 24 |
| Bokemeyer et al25 | 3 (Germany) | NR | No | Do-If | 16 vs 0 vs 0 | 16 vs 0 vs 0 |
| Cook et al26 | 29 (USA) | 1999–2007 | No | Ca-Cy-Et-Me-Th | 0 vs 0 vs 36 | 33 vs 2 vs 1 |
| Philippe-Chomette et al27 | >1 (France) | 1995–2006 | No | Various | 14 vs 0 vs 0 | 0 vs 0 vs 14 |
| Individual cases data | ||||||
| 55 studies (142 patients) | Various | Various | No | Various | 69 vs 61 vs 12 | 102 vs 21 vs 19 |
BMT, bone marrow transplant; Ca, carboplatin; Ci, cisplatin; Cy, cyclophosphamide; Do, Doxorubicin; Et, etoposide=Vepesid=VP 16; HDCT, high-dose chemotherapy; HSCT, autologous haematopoietic stem cell transplantation; If, ifosfamide; Me, melphalan; Mi, mitoxantrone; N, number; NR, information not reported in the article; PBSCT, peripheral blood stem cell transplant; Th, thiotepa.